A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS)

Recruiting

Phase 2

PimozideA Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS)

Sponsor:

University of Calgary

Code:

NCT03272503

Conditions

ALS

Amyotrophic Lateral Sclerosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pimozide 2mg/day (current) or 4 mg/day (study initiation)

Placebo Oral Tablet

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-19. This information was provided to ClinicalTrials.gov by University of Calgary on 2020-05-28.